Mount Sinai researchers have shown that shrinking liver tumors to a size that allows the patient to qualify for liver transplant results in excellent 10-year outcomes, validating current US policies for transplant eligibility.
Parissa Tabrizian, Associate Professor of Surgery at the Icahn School of Medicine at Mount Sinai, and colleagues explain in JAMA Surgery that liver transplant eligibility among people with hepatocellular carcinoma (HCC) has been guided by the Milan Criteria for more than 20 years. Read more from Inside Precision Medicine.